(Reuters) – The U.S Food and Drug Administration on Thursday approved Zogenix Inc’s drug to treat seizures associated with a rare form of childhood epilepsy known as Dravet syndrome. (https://reut.rs/3g2naBs)
The FDA last year had refused to fully review the marketing application for the treatment, and in February extended its review of the application by three months.
Dravet syndrome is a life-threatening, rare and chronic form of epilepsy, often characterized by severe and unrelenting seizures.
(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru; editing by Uttaresh.V)
